Funding for this research was provided by:
Terry Fox Research Institute (1023)
Received: 21 November 2019
Accepted: 7 January 2020
First Online: 24 February 2020
: D.W.S., J.M.C. and R.D.G. are inventors on a patent held by the National Cancer Institute that has been licensed by NanoString Technologies. C.S. has performed consultancy for Seattle Genetics, Curis Inc., Roche, AbbVie, Juno Therapeutics and Bayer, and has received research funding from Bristol-Myers Squibb and Trillium Therapeutics Inc. D.W.S. has performed consultancy for Janssen and Celgene and has received research funding from Roche/Genentech, Janssen and NanoString Technologies. R.D.G. has performed consultancy for Celgene. R.K. received travel support from Roche. D.V., A.S.G, K.J.S., J.M.C., L.H.S. and D.W.S. received institutional research funding from Roche. L.H.S. has performed consultancy and received honoraria from Amgen, Abbvie, Apobiologix, Celgene, Lundbeck, Janssen, Karyopharm, TG Therapeutics, Roche/Genentech, Teva and Takeda. K.J.S. received honoraria and provided consultancy to Bristol-Myers Squibb, Merck, Takeda, Verastem and Servier. A.S.G. received honoraria and provided consultancy to Janssen, AbbVie and Seattle Genetics. D.V. received honoraria from and participated in advisory boards for: Roche, Abbvie, Celgene, Seattle Genetics, Lundbeck, AstraZeneca, Nanostring, Janssen and Gilead.